About Lialda
Ulcerative Colitis: Impact on Patients
Professional Resources
Patient Education
Shire Commitment to GI
Register for More Information
Important Safety Information and Full Prescribing Information
Register to Receive Updates from Lialda and Shire GILialda for Patients		  

Ulcerative Colitis and Gastroenterology Professional Resources

The following resources are available to inform as well as provide updates to you and your practice about gastroenterology and digestive issues, and clinical studies and treatment options.

  • The American College of Gastroenterology (ACG) is a multidisciplinary association composed of gastroenterologists, surgeons, radiologists, hepatologists, pediatricians, pathologists, and others with a shared interest in the care of patients with digestive diseases. The ACG also offers local and national meeting opportunities including The ACG Annual Scientific Meeting and Postgraduate Course (http://www.acg.gi.org/acgmeetings/). feature excellent faculty and a clinical focus make the ACG Annual Scientific Meeting and Postgraduate Course the premier GI clinical event of the year. Network with your peers and share experiences from your practice. You will also get unparalleled access to faculty for in-depth discussions on a broad range of cutting edge topics for the GI physician

  • Founded in 1897, the American Gastroenterological Association (AGA) is dedicated to the mission of advancing the science and practice of gastroenterology. It is the oldest medical specialty organization in the United States.

  • Digestive Disease Week (DDW) is one of the largest and most important meetings for the GI professional. Every year it attracts more than 16,000 physicians, researchers, and academics from around the world who desire to stay up-to-date in their respective fields.

  • Two other government resources that can provide up-to-date professional information on UC are the National Guidelines Clearinghouse, which offers treatment guidelines for UC issued by many domestic and international medical groups, and ClinicalTrials.gov, an extensive database of ongoing clinical trials for virtually all disease states, including UC.

Other resources can be useful to both patients and health care professionals offering valuable tools and information and connecting patients:

  • The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is a branch of the National Institutes of Health (NIH) that focuses on diseases of the digestive tract and offers many resources for clinicians and patients.

  • MyIBD.org is a valuable resource for ulcerative colitis patients and their families. The site is dedicated to providing accurate information about ulcerative colitis and other inflammatory bowel diseases (IBD), including treatment options.

  • Founded in 1967, the Crohn’s and Colitis Foundation of America (CCFA) is a nonprofit, volunteer-driven organization dedicated to finding the cures for Crohn's disease and ulcerative colitis.

Next: Patient Education



  
 


Important Safety Information

  • Lialda tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of Lialda beyond
    8 weeks have not been established.

  • Lialda is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of Lialda. Caution should be exercised when treating patients with pyloric stenosis or those allergic to sulfasalazine. Mesalamine has been associated with an acute intolerance syndrome (3% of patients in clinical trials with mesalamine or sulfasalazine) that may be difficult to distinguish from a flare of inflammatory bowel disease. If acute intolerance syndrome is suspected, prompt withdrawal is required. Mesalamine-induced cardiac hypersensitivity reactions (myocarditis and pericarditis) have been reported. Reports of renal impairment have been associated with mesalamine medications. In patients with renal impairment, caution should be exercised, and Lialda should be used only if the benefits outweigh the risks. No information is available for patients with hepatic impairment.

  • Lialda is generally well tolerated. The majority of adverse events in the double-blind, placebo-controlled trials were mild or moderate in severity. In clinical trials (N=535), the most common treatment-related adverse events with Lialda 2.4 g/day, 4.8 g/day and placebo were headache (5.6%, 3.4% and 0.6%, respectively) and flatulence (4%, 2.8% and 2.8%, respectively). Pancreatitis occurred in less than 1% of patients during clinical trials and resulted in discontinuation of therapy with Lialda.



Home | Privacy Policy | Patient Site | Contact Us | Shire Corporate | Full Prescribing Information | Site Map | Unsubscribe | References

shire  ©2008 Shire US Inc., Wayne, PA 19087 | LIA-00244 | 09/08.
Lialda® is a registered trademark of Shire LLC. MMX® is a registered trademark owned by Cosmo Technologies Ltd, Ireland, a wholly-owned subsidiary of Cosmo Pharmaceuticals SpA.